Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 194

1.

Haemoglobin and haematocrit targets for the anaemia of chronic kidney disease.

Strippoli GF, Navaneethan SD, Craig JC.

Cochrane Database Syst Rev. 2006 Oct 18;(4):CD003967. Review.

PMID:
17054191
2.

Haemoglobin and haematocrit targets for the anaemia of chronic renal disease.

Strippoli GF, Manno C, Schena FP, Craig JC.

Cochrane Database Syst Rev. 2003;(1):CD003967. Review. Update in: Cochrane Database Syst Rev. 2006;(4):CD003967.

PMID:
12535495
3.

Hemoglobin targets for the anemia of chronic kidney disease: a meta-analysis of randomized, controlled trials.

Strippoli GF, Craig JC, Manno C, Schena FP.

J Am Soc Nephrol. 2004 Dec;15(12):3154-65.

4.

Parenteral versus oral iron therapy for adults and children with chronic kidney disease.

Albaramki J, Hodson EM, Craig JC, Webster AC.

Cochrane Database Syst Rev. 2012 Jan 18;1:CD007857. doi: 10.1002/14651858.CD007857.pub2. Review.

PMID:
22258974
5.

Frequency of administration of recombinant human erythropoietin for anaemia of end-stage renal disease in dialysis patients.

Cody J, Daly C, Campbell M, Donaldson C, Grant A, Khan I, Vale L, Wallace S, MacLeod A.

Cochrane Database Syst Rev. 2002;(4):CD003895. Review. Update in: Cochrane Database Syst Rev. 2005;(3):CD003895.

PMID:
12519614
6.

Antioxidants for chronic kidney disease.

Jun M, Venkataraman V, Razavian M, Cooper B, Zoungas S, Ninomiya T, Webster AC, Perkovic V.

Cochrane Database Syst Rev. 2012 Oct 17;10:CD008176. doi: 10.1002/14651858.CD008176.pub2. Review.

PMID:
23076940
7.

Early versus delayed erythropoietin for the anaemia of end-stage kidney disease.

Coronado Daza J, Martí-Carvajal AJ, Ariza García A, Rodelo Ceballos J, Yomayusa González N, Páez-Canro C, Loza Munárriz C, Urrútia G.

Cochrane Database Syst Rev. 2015 Dec 16;(12):CD011122. doi: 10.1002/14651858.CD011122.pub2. Review.

PMID:
26671531
8.

Recombinant human erythropoietin for chronic renal failure anaemia in pre-dialysis patients.

Cody J, Daly C, Campbell M, Donaldson C, Grant A, Khan I, Pennington S, Vale L, Wallace S, MacLeod A.

Cochrane Database Syst Rev. 2001;(4):CD003266. Review. Update in: Cochrane Database Syst Rev. 2005;(3):CD003266.

PMID:
11687180
9.

Androgens for the anaemia of chronic kidney disease in adults.

Yang Q, Abudou M, Xie XS, Wu T.

Cochrane Database Syst Rev. 2014 Oct 9;(10):CD006881. doi: 10.1002/14651858.CD006881.pub2. Review.

PMID:
25300168
10.

Frequency of administration of erythropoiesis-stimulating agents for the anaemia of end-stage kidney disease in dialysis patients.

Hahn D, Cody JD, Hodson EM.

Cochrane Database Syst Rev. 2014 May 28;(5):CD003895. doi: 10.1002/14651858.CD003895.pub3. Review.

PMID:
24872328
11.

Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers for adults with early (stage 1 to 3) non-diabetic chronic kidney disease.

Sharma P, Blackburn RC, Parke CL, McCullough K, Marks A, Black C.

Cochrane Database Syst Rev. 2011 Oct 5;(10):CD007751. doi: 10.1002/14651858.CD007751.pub2. Review.

PMID:
21975774
12.

Interventions for erythropoietin-resistant anaemia in dialysis patients.

Badve SV, Beller EM, Cass A, Francis DP, Hawley C, Macdougall IC, Perkovic V, Johnson DW.

Cochrane Database Syst Rev. 2013 Aug 26;(8):CD006861. doi: 10.1002/14651858.CD006861.pub3. Review.

PMID:
23979995
13.

A systematic review and economic evaluation of epoetin alpha, epoetin beta and darbepoetin alpha in anaemia associated with cancer, especially that attributable to cancer treatment.

Wilson J, Yao GL, Raftery J, Bohlius J, Brunskill S, Sandercock J, Bayliss S, Moss P, Stanworth S, Hyde C.

Health Technol Assess. 2007 Apr;11(13):1-202, iii-iv. Review.

14.

Recombinant human erythropoietin for chronic renal failure anaemia in pre-dialysis patients.

Cody J, Daly C, Campbell M, Donaldson C, Khan I, Rabindranath K, Vale L, Wallace S, Macleod A.

Cochrane Database Syst Rev. 2005 Jul 20;(3):CD003266. Review. Update in: Cochrane Database Syst Rev. 2016;1:CD003266.

PMID:
16034896
15.

Comparison of cellulose, modified cellulose and synthetic membranes in the haemodialysis of patients with end-stage renal disease.

MacLeod A, Daly C, Khan I, Vale L, Campbell M, Wallace S, Cody J, Donaldson C, Grant A.

Cochrane Database Syst Rev. 2001;(3):CD003234. Review. Update in: Cochrane Database Syst Rev. 2005;(3):CD003234.

PMID:
11687058
16.

Frequency of administration of recombinant human erythropoietin for anaemia of end-stage renal disease in dialysis patients.

Cody J, Daly C, Campbell M, Donaldson C, Khan I, Vale L, Wallace S, Macleod A.

Cochrane Database Syst Rev. 2005 Jul 20;(3):CD003895. Review. Update in: Cochrane Database Syst Rev. 2014;5:CD003895.

PMID:
16034913
17.

Vitamin D compounds for people with chronic kidney disease requiring dialysis.

Palmer SC, McGregor DO, Craig JC, Elder G, Macaskill P, Strippoli GF.

Cochrane Database Syst Rev. 2009 Oct 7;(4):CD005633. doi: 10.1002/14651858.CD005633.pub2. Review.

PMID:
19821349
18.

HMG CoA reductase inhibitors (statins) for dialysis patients.

Navaneethan SD, Nigwekar SU, Perkovic V, Johnson DW, Craig JC, Strippoli GF.

Cochrane Database Syst Rev. 2009 Apr 15;(2):CD004289. doi: 10.1002/14651858.CD004289.pub3. Review. Update in: Cochrane Database Syst Rev. 2009;(3):CD004289.

PMID:
19370598
19.

Darbepoetin for the anaemia of chronic kidney disease.

Palmer SC, Saglimbene V, Craig JC, Navaneethan SD, Strippoli GF.

Cochrane Database Syst Rev. 2014 Mar 31;(3):CD009297. doi: 10.1002/14651858.CD009297.pub2. Review.

PMID:
24683046
20.

HMG CoA reductase inhibitors (statins) for dialysis patients.

Navaneethan SD, Nigwekar SU, Perkovic V, Johnson DW, Craig JC, Strippoli GF.

Cochrane Database Syst Rev. 2009 Jul 8;(3):CD004289. doi: 10.1002/14651858.CD004289.pub4. Review.

PMID:
19588351

Supplemental Content

Support Center